“…A trend toward more faintness and falls was seen with the lower SBP targets in the SHEP and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials 29 but were not associated with lower BP treatment targets in the JATOS, VALISH, Studio Italiano Sugli Effetti CARDIOvascolari del Controllo della Pressione Arteriosa SIStolica, or Felodipine Event Reduction trials [31][32][33][34] or in the 80-year-old HYVET participants. 19 A recent report from the ACCORD trial, 42 in a cohort with diabetes mellitus and hypertension (mean age >62, 25% African American), found a nonsignificantly lower risk of falls (relative risk (RR) = 0.84, 95% CI = 0.54-1.29, P = .43) and nonspine fracture risk (hazard ratio (HR) = 0.79, 95% CI = 0.62-1.01, P = .06) in those treated to a SBP less than 120 mmHg than in those treated to a SBP less than 140 mmHg. Similar results were observed in another study, the Reasons for Geographic and Racial Differences in Stroke study, 43 which compared individuals (without CVD history) taking antihypertensive medications in three age groups (55-64, 65-74, ≥75) and found no association between SBP (120-139 vs >150 mmHg) and falls in any of the age groups.…”